Pharmacogenomics Conference 2020

Description

Pharmacogenomics (PGx) is the science of how an individual’s genetic background impacts response to medications. The field has left the research realm and has emerged as an important tool for clinical care. There is also a growing interest by consumers in PGx testing, fueled by direct-to-consumer availability of testing. Many academic and large private health systems have implemented PGx and now smaller non-academic centers are beginning or considering implementation into routine practice. Having a clear understanding of the current scientific evidence, emerging evidence, and knowledge of successful implementation pathways and examples are critical for successful launch. 

This two-day conference will provide PGx implementation education on a range of topics through lectures and smaller group breakout sessions. The first day will focus on general knowledge that supports drug-gene pairs commonly implemented in practice, and data emerging for new drug-gene pairs that may be in the pipeline for implementation. The efforts by CPIC in authoring guidelines and a behind-the-scenes look at the CPIC scientific review process will be presented. Strategies to return PGx results to patients, how to use PGx information in the absence of a guideline or in the setting of a simultaneous drug-drug interaction will be covered. The second day will focus on PGx best practices and strategies for successful implementation. Four well-established programs will present their PGx programs and share the successes and pitfalls they encountered during the development of their programs. Best practices in creating a multidisciplinary PGx team, selecting a laboratory for testing, how to use online tools such as PharmVar, cost effectiveness, genetic variants in minority populations, how PGx improves quality of care and safety, and PGx clinical decision support will be presented. 

Continuing Education credits will be offered for this 2-day conference

Registration opens January 15, 2020

Conference email: pgxconf@umn.edu

Target Audience

This conference would be useful for healthcare providers such as pharmacists, physicians, nurses, physician assistants, mental health providers, program managers and genetic counselors who are interested in implementing PGx into their personal practice or in their health system.

Objectives

Following completion of this activity, the learner will be able to: 

  1. Describe the scientific evidence supporting use of drug gene pairs currently implemented in clinical care. 

  2. Discuss the emerging evidence for new drug gene pairs that may be implemented into practice in the future. 

  3. Describe the challenges and how to approach pharmacogenomic guided testing in populations where data are limited data.

  4. Describe pharmacogenomic implementation efforts in the U.S. 

  5. Assess how to select a pharmacogenomic testing panel and testing laboratory appropriate for your practice.

  6. Assess how pharmacogenomic guided therapy could be applied in your practice setting.

  7. Discuss the emerging data that supports cost effectiveness of pharmacogenomic testing and the challenges related to assessing cost savings.

  8. Assess how to build clinical decision support for your clinical setting. 

  9. Discuss return of pharmacogenomic results to patients and communication to prescribers

Conference Schedule

Day 1:  Thursday, June 11, 2020

Day 1 will focus on general knowledge that supports drug-gene pairs commonly implemented in practice and data emerging for new drug-gene pairs. Moderated small breakout groups for the discussion of PGx cases will be offered.

8:00-8:15 AM

Welcome and Introduction to Day 1

Pamala Jacobson, PharmD, FCCP, Conference Chair; University of Minnesota College of Pharmacy

8:15-9:00 AM

Keynote:  

Larissa Cavallari, PharmD, BCPS, FCCP; University of Florida, “Future of Pharmacogenomics”

Session 1: Primary Care Pharmacogenomics

Moderator: Jacob Brown, PharmD, MS; University of Minnesota College of Pharmacy

Speakers: 

9:00-9:30    Jeffrey Bishop, PharmD, BCPP, FCCP; University of Minnesota College of Pharmacy — “Evidence for Implementation of PGx in Psychiatry and Emerging Areas (SNRI, SSRI update and antipsychotics)”

9:30-10:00    Sony Tuteja, PharmD, MS, BCPS, FAHA; University of Pennsylvania Perelman School of Medicine — “Evidence for Implementation of PGx in Cardiovascular and Emerging Areas”

10:30-11:00    Laura B. Ramsey, PhD; Cincinnati Children’s Hospital Medical Center — “Evidence for Implementation of PGx in Pediatrics and Future Directions” 

11:00-11:30    D. Max Smith, PharmD, BCPS; MedStar Health and Georgetown University School of Medicine — “Evidence for Implementation of PGx for Opioids”

11:30-12:00    Valentina Shakhnovich, MD; University of Missouri-Kansas City School of Medicine and Children’s Mercy Hospital & Clinics — “Evidence for Implementation of PGx for PPIs”

 

Session 2: Pharmacogenomics to Improve Drug Safety and What’s New At Clinical Pharmacogenetics Implementation Consortium (CPIC) 

Moderator: R. Stephanie Huang, PhD; University of Minnesota College of Pharmacy  

Speakers: 

1:00-1:30    Jason Karnes, PharmD, PhD, BCPS, FAHA; University of Arizona College of Pharmacy — “Evidence for Implementation of PGx for Hypersensitivity Reactions and Future Directions”

1:30-2:00    Pamala Jacobson, PharmD, FCCP; University of Minnesota College of Pharmacy — “Evidence for Implementation of PGx in Transplantation (i.e. tacrolimus, voriconazole) and Future Directions”

2:00-2:30    Kelly Caudle, PharmD, PhD, BCPS, CPIC Director; St. Jude Children’s Research Hospital — “Clinical Pharmacogenetic Implementation Consortium and Emerging Regulatory Issues from the FDA”

2:30-3:00    Jacob Brown, PharmD, MS; University of Minnesota College of Pharmacy — “A Behind-the-Scenes Look at the CPIC Evidence Review Process for Drug-Gene Pairs”

Session 3: Pharmacogenomic Complexities

Moderator:  Robert J. Straka, PharmD, FCCP; University of Minnesota College of Pharmacy

3:30-4:10 PM    Case Session 1 

4:20-5:00 PM     Case Session 2

Case 1. Robert J. Straka, PharmD, FCCP; University of Minnesota College of Pharmacy — “How to Navigate Drug-Drug Interactions in the Patient with Pharmacogenomic Variants: PGx Phenoconversion”

Case 2. Eric T. Matey PharmD, RPh, BCACP, MBA; Mayo Clinic — “Return of Pharmacogenomic Results to the Patient via an e-Consult”

Case 3. Elise Durgin, PharmD; Children’s Minnesota — “Providing PGx-Guided Care in the Absence of Clinical Guidelines (3 complex patient cases)”

5:00-5:15 PM
Concluding Remarks and Book Drawing 
Pamala Jacobson, PharmD, FCCP, Conference Chair

5:15-6:30 PM
Networking session 
Conference attendees are invited to attend an open session for networking with the speakers and others interested in PGx. Hors d'oeuvres and non-alcoholic beverages will be served. A cash bar will be available

 

Day 2:  Friday, June 12, 2020

Implementation of PGx varies depending on the care delivery system, provider and laboratory expertise, and types of patients served. Day 2 will describe science and successful PGx implementation at 4 centers representing an academic health system, a research and a non-research intensive children’s hospital, and a large rural health system. PGx implementation best practices and strategies, and potential difficulties in implementation will be presented. Topics including cost effectiveness, improving quality of care, selecting a PGx testing laboratory and PGx rule building and clinical decision support. 

8:00-8:10 AM

Welcome and Introduction to Day 2

Pamala Jacobson, PharmD, FCCP, Conference Chair

Session 4: Implementation Science and Examples of PGx Implementations

Moderator:  David Gregornik, PharmD, BCOP; Children’s Minnesota

Speakers: 

8:15-8:45    Todd D. Sorensen, PharmD, FAPhA, FCCP; University of Minnesota College of Pharmacy — “Pathway for Implementation of a Healthcare Innovation: PGx”

8:45-9:15    Sara L. Van Driest, MD, PhD; Vanderbilt University Medical Center — “Implementation at Vanderbilt University, Nashville, TN”

9:15-9:45    Cyrine Haidar, PharmD, BCPS, BCOP; St. Jude Children’s Research Hospital — “Implementation at St. Jude Children’s Research Hospital, Memphis, TN”

10:15-10:45    David Gregornik, PharmD, BCOP; Children’s Minnesota — “Implementation at Children’s Minnesota”

10:45-11:15    April Schultz, PharmD; Sanford Health — “Implementation at Sanford Health, Sioux Falls, SD”

Session 5: Important Considerations in Pharmacogenomic Implementation: Avoiding the Pitfalls

Moderator:  William Oetting, PhD; University of Minnesota College of Pharmacy

Speakers: 

1:00-1:30        Pedro J. Caraballo, MD; Mayo Clinic— “Creating a Multidisciplinary Model to Implement Pharmacogenomics

1:30-2:00        Vicki Pratt, PhD, FACMG; Indiana University School of Medicine —“Not All PGx Assays are the Same: Selection of a PGx Assay That’s Right for Your Patients”

2:00-2:30        Andrea Gaedigk, MS, PhD; University of Missouri-Kansas City School of Medicine and Children’s Mercy Hospital & Clinics —“The Pharmacogene Variation (PharmVar) Consortium and Standardization of Pharmacogene Variation to Facilitate Interpretation of Test Results” 

3:00-3:30        Donald K. Baker, PharmD, MBA; St. Jude Children’s Research Hospital —“Development of PGx Rules and Clinical Decision Support Tools”

3:30-4:00        Minoli Perera, PharmD, PhD; Northwestern University Feinberg School of Medicine — “Special Considerations for Implementation of PGx in Minority Populations”

4:00-4:30        Joel Farley, PhD, RPh, FAPhA — “The Evidence for Cost Effectiveness and Quality Improvement of Pharmacogenomic Services”

 

4:30-5:00pm
Concluding Remarks and Book Drawing
Pamala Jacobson, PharmD, FCCP, Conference Chair

 

Sponsored and Organized by College of Pharmacy Department of Experimental and Clinical Pharmacology

Pamala Jacobson, PharmD, FCCP, Conference Chair

Jeffrey Bishop, PharmD, MS, FCCP, BCPP

Stephanie Huang, PhD, MS, MD

Jacob Brown, PharmD, MS

Robert Straka, PharmD, FCCP

David Stenehjem, PharmD, BCOP

Brian Van Ness, PhD

William Oetting, PhD

David Gregornik, PharmD 

Accreditation logo

 

 

 

 

Accreditation

In support of improving patient care, University of Minnesota, Interprofessional Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Credit Designation Statements

Accreditation Council for Pharmacy Education (ACPE)

This activity is eligible for ACPE contact hours; the number of hours is pending.

American Medical Association (AMA)

This activity has been approved for AMA PRA Category 1 Credit™. Determination of exact number of credits is pending.

American Nurses Credentialing Center (ANCC)

This activity is eligible for ANCC contact hours; the number of hours is pending.

Other Healthcare Professionals

Other healthcare professionals who participate in this CE activity may submit their statement of participation to their appropriate accrediting organizations or state boards for consideration of credit. The participant is responsible for determining whether this activity meets the requirements for acceptable continuing education.

Date/time:

Thursday, June 11th, 2020 to Friday, June 12th, 2020
8:00am to 5:00pm

Location:

TCF Bank Stadium

University of Minnesota

Minneapolis, MN

Pharmacist walking on DNA